Loading clinical trials...

ACTIVE_NOT_RECRUITINGPHASE4

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862•Vanderbilt University Medical Center

Summary

The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.

Detailed Description

The Primary Investigator's central hypothesis is that activation of thrombotic pathways and downstream effectors of factor Xa signaling contribute to the development of PAD and its complications. Aim 1: To assess the impact of rivaroxaban on macrovascular endothelial function in a randomized, double-blind, placebo-controlled crossover intervention in humans with PAD. Aim 2: To assess the impact of rivaroxaban on PAR-1-mediated platelet activation in addition to its pleiotropic effects on thrombosis, thrombolysis, and inflammation in a randomized, double-blind, placebo-controlled crossover intervention in humans with PAD.

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•History of peripheral artery disease (PAD) defined as:
•Previous aorto-femoral bypass surgery, limb bypass surgery, or percutaneous transluminal angioplasty revascularization of the iliac or infra-inguinal arteries, or
•Previous limb or foot amputation for arterial vascular disease, or
•An ankle/arm blood pressure (BP) ratio less than 0.90, or
•Significant peripheral artery stenosis (≥50%) documented by angiography, or by duplex ultrasound, or
•An ankle-brachial index (ABI) greater than 1.4 with a toe-brachial index (TBI) less than 0.7 AND
•Willing and able to provide written informed consent
•Receiving aspirin therapy prior to enrollment

Exclusion Criteria

•High risk of bleeding
•Stroke within 1 month of any history of hemorrhagic or lacunar stroke
•Severe heart failure with known ejection fraction less than 30% or New York Heart Association (NYHA) class III or IV symptoms
•Estimated glomerular filtration rate less than 15 mL/min/1.73m2
•Need for dual-antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy
•Known non-cardiovascular disease that is associated with poor prognosis (e.g. metastatic cancer) or that increases the risk of an adverse reaction to study interventions
•History of hypersensitivity or known contraindication to rivaroxaban or aspirin
•Systemic treatment with strong inhibitors of both CYP 3A4 and p-glycoprotein (e.g. systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus \[HIV\]-protease inhibitors, such as ritonavir), or strong inducers of CYP 3A4, i.e. rifampicin, rifabutin, phenobarbital, phenytoin, and carbamazepine
•Any known hepatic disease associated with coagulopathy
•Subjects who are pregnant, breastfeeding, or are of childbearing potential, and sexually active and not practicing an effective method of birth control (e.g. surgically sterile, prescription oral contraceptives, contraceptive injections, intrauterine device, double- barrier method, contraceptive patch, male partner sterilization)
+6 more criteria

Locations (1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Key Dates

Start Date

April 19, 2022

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2026

Last Updated

December 24, 2025

Enrollment

ESTIMATED participants

Conditions

Peripheral Arterial Disease

Interventions

Rivaroxaban 2.5 Mg Oral Tablet

DRUG

Placebo

DRUG

Aspirin 81Mg Ec Tab

DRUG

Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Disease Using Novel Imaging

NCT07472049

Peripheral Arterial DiseaseChronic Limb Threatening Ischemia

View study

RECRUITING

Advanta VXT and Flixene PMCF Registry

NCT07161583

Peripheral Arterial Disease

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

Inclusion Criteria

Exclusion Criteria

Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Disease Using Novel Imaging

Advanta VXT and Flixene PMCF Registry

Intervascular Post-Market Clinical Follow-Up (PMCF) Registry

VITUS Post-Market Registry

The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)

Randomized Clinical Trial for Ewing Amputation in the VA